Te lymphoma pūtau-B nui horapa (DLBCL)-04

Te Urupare Whakamiharo o te Wā Moata a Mr. Monger: He Tūmanako Hou te Maimoatanga CD19/CD20 CAR-T Takirua mō te DLBCL kua Hokihoki

Papamuri o te Tūroro 

I kitea a Rodney Charles Monger, he tāne 68-tau te pakeke nō tāwāhi, he mate pukupuku lymphoma nui-B (DLBCL) e horapa ana i ngā tau e toru ki muri. I rapu ia i te tiaki matatau i te Hōhipera Matepukupuku o Tianjin i te marama o Ākuhata 2025. I whakaūtia e te koiora o te kōpū lymph o te kaki he lymphoma pūtau-B urutomo nō te pokapū germinal. He tino pai te immunohistochemistry mō te CD20, CD19, me te CD10, me te nui o te whakaaturanga o te Bcl-6, Bcl-2 (70%+), me te c-MYC (60%+). I whakaatuhia e ngā whakamātautau ira te whakarerekētanga o te BCL2 e FISH me ngā whakarerekētanga ira i roto i ngā ira EZH2, KMT2D, TNFRSF14, NRAS, me te TPMT—he tohu e rite ana ki te kōtaha kaha, mōrearea nui.

Te Haerenga Maimoatanga o Mua 

I te marama o Ākuhata 2025, i whiwhi a Mr. Monger i te pola i honoa ki te aukati BTK me te lenalidomide. I muri mai ka whiwhi ia i te rongoā mate pukupuku lymphodepletion FC (fludarabine + cyclophosphamide). Ahakoa ēnei mahi, i mau tonu te ātete o tōna mate, ā, i akiaki te tīma hauora ki te taunaki i te rongoā pūtau CAR-T CD19/CD20 arotahi-rua a Bioocus.

I te 8 o Hepetema, 2025, i whiwhi a Mr. Monger i te werohanga o ngā pūtau CD19/CD20 CAR-T autologous. He mea whakamiharo, i wheako ia kāore he mate tukunga cytokine (CRS)me te mate pukupuku roro e pā ana ki ngā pūtau kore-pūnaha ārai mate (ICANS)—he akoranga maeneene i muri i te werohanga i āhei ai ia ki te noho pumau me te hihiri mai i te rā tuatahi.

Te Whanuitanga o te Pūtau CAR-T: Tere, Pakari hokiI roto i te aroturukitanga toto ā-taha, i kitea te whānui whakamiharo o ngā pūtau CAR-T, ā, i whakaū i te pai o te whakaurunga me te tipu:

• D4 i muri i te werohanga(Hepetema 12): Ko ngā pūtau CAR19+ he 0.50% o ngā pūtau T CD3+ (uara tino 6.04 × 10⁷/L); ngā pūtau CAR20+ he 0.41% (4.96 × 10⁷/L).
• D7(Hepetema 15): I piki ake a CAR19+ ki te 1.68% (1.40 × 10⁷/L); CAR20+ ki te 1.63% (1.36 × 10⁷/L).
• D10(Hepetema 18): I tae atu a CAR19+ 43%o ngā pūtau CD3+ T (uara tino 3.13 × 10⁸/rita); kua tae ki te CAR20+ 32.74%(uara tino 3.26 × 10⁸/rita).

I whakaatuhia anō hoki e te flow cytometry te tohatoha taurite puta noa i ngā huinga CD4+ me CD8+, me te kaha o te whakaaturanga CAR takirua. I whakaatuhia e ngā ānau aroturuki hihiri he wāhanga whānui taupū mārama, e whakaatu ana i te whai huatanga o te hoahoa CD19/CD20 takirua ki te whakatairanga i te pumau me te tipu o te CAR-T i roto i te tinana ora.

Te Āhua o Nāianei me te Manaaki Tautoko 

I te arotakenga hou (D10), kei te pai tonu te āhua o Mr. Monger i roto i te hōhipera. Kei te tango ia i ngā rongoā ā-waha kua whakaritea mōna, tae atu ki te acyclovir, te sulfamethoxazole matū, te orelabrutinib, te lenalidomide, me ngā rongoā tautoko, me te aro turuki tonu i ngā tatauranga toto, te mahi ate me te whatukuhu, me ngā tohu mumura e ai ki te mahere tukunga.

I whakaratohia e te tīma Bioocus te tautoko whānui, arotahi ki te tūroro puta noa i te wā: he wāhi noho whakamarie, he kai totika, he āwhina kawe waka, me te tohutohu hinengaro mō Mr. Monger me tōna whānau. Nā tēnei huarahi whānui i āwhina i a ia ki te aro katoa ki te whakaora.

He Karere o te Tumanako 

Ko te take a Mr. Monger e whakaatu ana i te kaha whakarerekētanga o te rongoā Bioocus takirua CD19/CD20 CAR-T mō ngā tūroro he DLBCL kua hoki whakamuri/he uaua ki te rongoā. Ko te tere me te kaha o te horapa o ngā pūtau CAR-T me te kore he paitini nui e whakaatu ana i te āhua haumaru pai o te hua me te kaha ārai-pukupuku - ahakoa i roto i te tūroro pakeke ake he nui ngā āhuatanga ngota morearea.

He mea whakahīhī ki a mātou te tautoko i ngā tūroro pērā i a Mr. Monger i tā rātou hokinga mai ki te hauora. Ko ngā kōrero pēnei i āna e whakakaha ake ana i tō mātou whakapau kaha ki te whakarato i ngā maimoatanga pūtau auaha, whakarerekē-ora me te tiaki whaiaro.

Ka tukuna tēnei take me te whakaae a te tūroro. Tērā pea ka rerekē ngā hua; ka whakawhirinaki ngā putanga CAR-T ki te koiora o te mate takitahi me ngā āhuatanga haumanu. Mō ētahi atu kōrero, ki te tūhura rānei i ngā kōwhiringa maimoatanga, tirohia tā mātou whārangi CAR-T Therapy for Non-Hodgkin Lymphoma.